<DOC>
	<DOCNO>NCT01349803</DOCNO>
	<brief_summary>This study primarily safety study . The primary secondary endpoint base 24-hour Holter monitor assessment obtain Day 14 relative baseline .</brief_summary>
	<brief_title>PT003 MDI Cardiovascular Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Key Signed write informed consent 40 80 year age Clinical history COPD airflow limitation fully reversible Females nonchild bear potential female child bear potential negative pregnancy test ; acceptable contraceptive method Current/former smoker least 10 packyear history cigarette smoke A measure post bronchodilator FEV1/FVC ratio &lt; = 0.70 A measure post bronchodilator FEV1 &gt; = 750ml 30 % predict &lt; = 80 % predict normal value Able change COPD treatment require protocol Acceptable baseline ( Visit 2 ) Holter monitor record Key Women pregnant lactate Primary diagnosis asthma Alpha1 antitrypsin deficiency cause COPD Active pulmonary disease Prior lung volume reduction surgery Abnormal chest Xray ( CT scan ) due presence COPD Hospitalized due poorly control COPD within 3 month Screening Clinically significant medical condition preclude participation study ( e.g . clinically significant abnormal ECG , uncontrolled hypertension , glaucoma , symptomatic prostatic hypertrophy ) Cancer complete remission least 5 year Treatment investigational study drug participation another clinical trial study within last 30 day 5 half life Clinically significant abnormal finding baseline Holter record Patients pacemaker ICD/CRT/CRT_D device Other inclusion/exclusion criterion define protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>